• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CytoCore Enters Technology Transfer Research and Development Agreement With University Hospitals of Cleveland and Case Western Reserve University

Posted on: Monday, 13 February 2006, 12:01 CST

CytoCore, Inc. (OTCBB: MCDG.OB) and University Hospitals of Cleveland (UHC) and Case Western Reserve University (CASE) today announced the signing of a joint research and development program between CytoCore and University Hospitals of Cleveland and Case Western Reserve University. CytoCore, a bio-molecular cancer screening company, is bringing forward the next generation of biomolecular products to provide better cervical cancer solutions.

CytoCore's CEO, Dr. David Weissberg said, "This new agreement with University Hospitals of Cleveland and Case Western Reserve University is a major milestone for CytoCore. With this agreement, we are expanding and strengthening our partnership with these two organizations, which together form a world class medical teaching and research partnership. This expanded strategic relationship gives CytoCore access to top physicians and scientists and cutting edge medical research and products. We are extremely pleased and excited with our new relationship with these two institutions and their research scientists and their clinicians. UHC and CASE have expressed their enthusiasm and support for CytoCore which will give the two Institutions a very exciting commercial product partnership. There is real excitement with all the parties for the synergy that is evident in our new product portfolio and plans."

From this partnership, CytoCore will be expanding its research capability and product portfolio with several announcements. These new developments are expected to accelerate the successful testing and development of the Company's core products, while also significantly expanding the Company's product offerings. CytoCore expects to grow from a Cyto-Screening company to a Cyto-Diagnostic Company. In addition, it expects to offer a unique therapeutic device that fills the major vacuum in today's cervical cancer screening and treatment menu.

Mr. Phil Cola, Director of Clinical Research at University Hospitals Cleveland stated, "We are very enthused by the opportunity that CytoCore presents for UHC to assist in the commercialization of several cutting edge medical technologies we are licensing to them, augmenting their potent mix of technology in the cervical cancer screening area. With these additional new technologies, we see the combination of products coming together to build a unique capability in this important area of women's health. CytoCore's organization appears to have the management team, the capability and commitment to bring these products successfully to market. We are fully committed helping that occur."

Mr. Eric Cottington, Director of Research at Case Western Reserve University stated, "We work very closely with University Hospitals as many of our faculty practice at UHC. CASE has been working diligently over the past several years to successfully expand our technology transfer activities to bring the fruits of our research to the commercial market, and CytoCore is an example of this partnership process in action. They are receiving two cutting edge medical technologies from our research staff that fit perfectly with their existing products, and which should substantially enhance their capabilities and offerings."

About University Hospitals of Cleveland: Founded in 1866, University Hospitals of Cleveland is a 947-bed tertiary medical center specializing in adult/pediatric medical and surgical specialties. UHC is also the primary affiliate of Case Western Reserve University. Together, they form the largest center for biomedical research in the State of Ohio. As the research arm of University Hospitals of Cleveland, the Center for Clinical Research focuses on translational research, taking fundamental advances in biomedical research and applying them to improvements in healthcare. This is achieved through a balanced approach involving federal-funded research, sponsored research agreements with the pharmaceutical, biotechnology and medical device industries, and a century-long partnership with Case Western Reserve University. The Center for Clinical Research is designed to aggressively translate fundamental advances in scientific knowledge into advances in the clinical medicine by establishing new alliances with the pharmaceutical, biotechnology and medical device industries. More information is available at: http://www.uhhs.com/

About Case Western Reserve University: Case is among the nations leading research institutions. Founded in 1826 and shaped by the unique merger of the Case Institute of Technology and Western Reserve University, Case is distinguished by its strengths in education, research, service and experiential learning. Located in Cleveland, Case offers nationally recognized programs in the Arts and Sciences, Dental Medicine, Engineering, Law, Management, Medicine, Nursing and Social Services. Over the past several years, Case has moved into the top tier of national universities in terms of licensing revenue from successful technology transfer partnerships, exceeding the national averages in almost all key metrics of innovation. More information is available at: http://www.case.edu/

About CytoCore Inc: CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Source: Business Wire

More News in this Category